Rheumatoid Arthritis | TreatmentTrends | EU5 | 2014

launch Related Market Assessment Reports

• Rheumatoid Arthritis – Landscape & Forecast – Disease Landscape & Forecast

  May 2023

  Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…

• Rheumatoid Arthritis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

  May 2023

  The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…

• Rheumatoid Arthritis – Epidemiology – Extrapolated Worldwide Coverage

  January 2023

  Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key rheumatoid arthritis patient populations, covering 171 countries and…

• Rheumatoid Arthritis – Epidemiology – Europe

  Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…

• Rheumatoid Arthritis – Epidemiology – Emerging Markets

  Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…